Bupivacaine plus Lidocaine — Competitive Intelligence Brief

Bupivacaine plus Lidocaine (Bupivacaine plus Lidocaine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Local anesthetic combination. Area: Anesthesia / Pain Management.

marketed Local anesthetic combination Voltage-gated sodium channels Anesthesia / Pain Management Small molecule

Target snapshot

Bupivacaine plus Lidocaine (Bupivacaine plus Lidocaine) — University of Alabama at Birmingham. Bupivacaine and lidocaine are local anesthetics that block sodium channels in nerve cell membranes, preventing the initiation and conduction of nerve impulses.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Bupivacaine plus Lidocaine TARGET	Bupivacaine plus Lidocaine	University of Alabama at Birmingham	marketed	Local anesthetic combination	Voltage-gated sodium channels
Hyperbaric bupivacaine+Morphine	Hyperbaric bupivacaine+Morphine	Fundación Pública Andaluza Progreso y Salud	marketed	Local anesthetic + opioid combination	Voltage-gated sodium channels (bupivacaine); mu opioid receptors (morphine)
Propofol/Lidocaine	Propofol/Lidocaine	NYU Langone Health	marketed	Intravenous anesthetic combination	GABA-A receptor (propofol); voltage-gated sodium channels (lidocaine)
Remifentanil+Lidocaine	Remifentanil+Lidocaine	The First Affiliated Hospital of Zhengzhou University	marketed	Opioid analgesic + Local anesthetic combination	Mu-opioid receptor (remifentanil); Voltage-gated sodium channels (lidocaine)
ropivacaine and ketorolac	ropivacaine and ketorolac	University of Aarhus	marketed	Local anesthetic + NSAID combination	Voltage-gated sodium channels (ropivacaine); COX-1 and COX-2 (ketorolac)
Bupivacaine-fentanyl elective group	Bupivacaine-fentanyl elective group	Conrad Arnfinn Bjørshol	marketed	Local anesthetic with opioid analgesic combination	Voltage-gated sodium channels (bupivacaine); mu opioid receptor (fentanyl)
carbamazepine ER (Equetro)	carbamazepine ER (Equetro)	Massachusetts General Hospital	marketed	Anticonvulsant; mood stabilizer	Voltage-gated sodium channels

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Local anesthetic combination class)

1. University of Belgrade · 2 drugs in this class
2. Cedars-Sinai Medical Center · 1 drug in this class
3. Cutia Therapeutics（Wuxi）Co.,Ltd · 1 drug in this class
4. East Carolina University · 1 drug in this class
5. Galderma R&D · 1 drug in this class
6. Hadassah Medical Organization · 1 drug in this class
7. University of Alabama at Birmingham · 1 drug in this class
8. University of New Mexico · 1 drug in this class
9. Ain Shams University · 1 drug in this class
10. University of Wisconsin, Madison · 1 drug in this class